Jochen Decaestecker

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

MELD score to predict outcome in adult patients with non‐acetaminophen‐induced acute liver failure

Aezam Katoonizadeh, Jochen Decaestecker, Alexander Wilmer et al. · Liver International · 2007 · 119 citations

The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson’s disease

Aurélie de Rus Jacquet, Melanie Alpaugh, Hélèna L. Denis et al. · Nature Communications · 2023 · 98 citations · Full text

Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after <scp>HB</scp> eAg seroconversion is associated with high relapse rates and fatal outcomes

Stijn Van Hees, Stefan Bourgeois, Hans Van Vlierberghe et al. · Alimentary Pharmacology & Therapeutics · 2018 · 50 citations · Full text

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C‐infected patients treated with direct‐acting antivirals with and without pegylated interferon: A Belgian experience

Rob Bielen, Christophe Moreno, Hans Van Vlierberghe et al. · Journal of Viral Hepatitis · 2017 · 44 citations · Full text

Immunodeficiencies, Immunology, Pathology +21